Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375470 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4025191 | 0.80 | SMN1; SMN2 (0.45) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7105911 | 0.80 | CA1 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15674212 | 0.80 | TOP1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31145742 | 0.76 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL971062 | 0.76 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL809133 | 0.76 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4590099 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1L3MBTL1MAPTHPGD | |
| SCHEMBL10412063 | 0.76 | CA12 (0.32) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5675636 | 0.76 | IRAK4 (0.43) | CA1CA2CA7CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 696 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| CN-118754917-B | Alpha-diimine ligand compound, nickel complex, composite complex, preparation method and application thereof | 安徽中科科乐化工科技有限责任公司 | 2025-01-17 | — | — | CN | claimed |
| CN-118754917-A | Alpha-diimine ligand compound, nickel complex, composite complex, preparation method and application thereof | 安徽中科科乐化工科技有限责任公司 | 2024-10-11 | — | — | CN | claimed |
| CN-118184705-A | Preparation method and application of diphosphine palladium complex | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118184706-A | Diphosphine palladium complex and application thereof | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114044753-A | Small molecular compound with anti-tumor metastasis function and preparation method thereof | 广州市朝利良生物科技有限公司 | 2022-02-15 | — | — | CN | claimed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | claimed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | claimed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | claimed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | claimed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| EP-0977739-B1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORP (US) | 2003-10-29 | — | — | EP | claimed |
| EP-1064286-A1 | SYNTHESIS OF ARYL BORONIC ACIDS | BOULDER SCIENTIFIC COMPANY (US) | 2001-01-03 | — | — | EP | claimed |
| EP-0977739-A1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-02-09 | — | — | EP | claimed |
| WO-1999064428-A1 | SYNTHESIS OF ARYL BORONIC ACIDS | BOULDER SCIENTIFIC COMPANY (US) | 1999-12-16 | — | — | WO | claimed |
| US-5998620-A | Synthesis of intermediates useful in preparing tricyclic compounds | SCHERING CORPORATION (US) | 1999-12-07 | — | — | US | claimed |
| WO-1998042676-A1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 1998-10-01 | — | — | WO | claimed |
| US-5623087-A | Method for preparation of optically active diarylalanines | NDSU-RESEARCH FOUNDATION (US) | 1997-04-22 | — | — | US | claimed |
| EP-0048555-A1 | Amino-1,2,4-triazole derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1982-03-31 | — | — | EP | claimed |
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| EP-4034610-B1 | DIHYDROQUINOLINE PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2025-09-10 | — | — | EP | disclosed |
| US-12404448-B2 | Dihydroquinoline photochromic compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2025-09-02 | — | — | US | disclosed |
| EP-3351533-B1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| CN-118754917-B | Alpha-diimine ligand compound, nickel complex, composite complex, preparation method and application thereof | 安徽中科科乐化工科技有限责任公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-118754917-A | Alpha-diimine ligand compound, nickel complex, composite complex, preparation method and application thereof | 安徽中科科乐化工科技有限责任公司 | 2024-10-11 | — | — | CN | disclosed |
| WO-2024168037-A2 | COMPOUNDS FOR TREATING OPIOID MISUSE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-114466913-B | Dihydro quinoline photochromic compounds | 光学转变有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-118184705-A | Preparation method and application of diphosphine palladium complex | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184705-A | Preparation method and application of diphosphine palladium complex | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184996-A | Ternary polar polyketone and preparation method thereof | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184997-A | Binary polar polyketone and preparation method thereof | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| CN-118184706-A | Diphosphine palladium complex and application thereof | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-4019607-B1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INT (FR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240092739-A1 | COMPOUNDS AND METHODS OF USE | VENTHERA, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-117567511-A | Complex, complex catalyst, and preparation method and application thereof | 合肥中科科乐新材料有限责任公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20240052235-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (FR) | 2024-02-15 | — | — | US | disclosed |
| CN-117069717-A | 2, 6-naphthyridine micromolecule derivative and preparation method thereof | 江汉大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-4274828-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2023-11-15 | — | — | EP | disclosed |
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-116783168-A | Electrochromic compounds and optical articles comprising the same | 依视路国际公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116635370-A | Process for preparing N- (bis (4-methoxyphenyl) methyl) -6-oxo-2- (pyridazin-3-yl) -1, 6-dihydropyrimidine-5-carboxamide | 英特维特国际股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230115176-A1 | Complement Modulators and Related Methods | RA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| CN-115449529-A | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20220333004-A1 | Dihydroquinoline Photochromic Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2022-10-20 | — | — | US | disclosed |
| CN-113952295-B | Anti-tumor metastasis medicine and application thereof | 广州市朝利良生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114044753-B | Small molecular compound with anti-tumor metastasis function and preparation method thereof | 广州市朝利良生物科技有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-4034610-A1 | DIHYDROQUINOLINE PHOTOCHROMIC COMPOUNDS | Transitions Optical, Ltd. (IE) | 2022-08-03 | — | — | EP | disclosed |
| CN-110382503-B | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2022-07-19 | — | — | CN | disclosed |
| WO-2022150174-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Global Enterprises Ltd. (BM) | 2022-07-14 | — | — | WO | disclosed |
| US-20220211692-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | AbbVie Global Enterprises Ltd. (BM) | 2022-07-07 | — | — | US | disclosed |
| WO-2022136020-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (FR) | 2022-06-30 | — | — | WO | disclosed |
| EP-4019607-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (FR) | 2022-06-29 | — | — | EP | disclosed |
| CN-110317169-B | 1-substituted isoquinolone compound and preparation method thereof | 复旦大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-114466913-A | Dihydroquinoline photochromic compounds | 光学转变有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-11279710-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2022-03-03 | — | — | US | disclosed |
| CN-114044753-A | Small molecular compound with anti-tumor metastasis function and preparation method thereof | 广州市朝利良生物科技有限公司 | 2022-02-15 | — | — | CN | disclosed |
| EP-3947352-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA Pharmaceuticals, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113952295-A | Anti-tumor metastasis medicine and application thereof | 广州市朝利良生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
| EP-3904337-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM Wako Pure Chemical Corporation (JP) | 2021-11-03 | — | — | EP | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| EP-3865474-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2021-08-18 | — | — | EP | disclosed |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2021-08-05 | — | — | US | disclosed |
| CN-113166043-A | Electrolyte for sulfur-based magnesium battery | 富士胶片和光纯药株式会社 | 2021-07-23 | — | — | CN | disclosed |
| CN-108884070-B | Pyridyl derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-3736270-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| EP-3736267-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2021-05-05 | — | — | EP | disclosed |
| US-10988454-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-27 | — | — | US | disclosed |
| US-10981890-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2021-04-20 | — | — | US | disclosed |
| WO-2021058114-A1 | DIHYDROQUINOLINE PHOTOCHROMIC COMPOUNDS | TRANSITIONS OPTICAL, LTD. (IE) | 2021-04-01 | — | — | WO | disclosed |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2021-03-02 | — | — | US | disclosed |
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10844041-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| US-10844042-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-24 | — | — | US | disclosed |
| CN-111954664-A | Cystic fibrosis transmembrane conductance regulator and methods of use | 艾伯维海外有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-3736270-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| EP-3736267-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-11-11 | — | — | EP | disclosed |
| US-10829473-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE OVERSEAS S.À.R.L. (LU) | 2020-11-10 | — | — | US | disclosed |
| EP-3681864-B1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-10-28 | — | — | EP | disclosed |
| EP-3440069-B1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020205501-A1 | COMPLEMENT MODULATORS AND RELATED METHODS | RA PHARMACEUTICALS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277273-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2020-09-03 | — | — | US | disclosed |
| US-10745412-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3681864-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie Overseas S.à r.l. (LU) | 2020-07-22 | — | — | EP | disclosed |
| WO-2020138377-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | 富士フイルム和光純薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-20200199147-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2020-06-25 | — | — | US | disclosed |
| US-10647675-B2 | Biaryl derivative and medicine containing same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2020-05-12 | — | — | US | disclosed |
| CN-110382503-A | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110317169-A | A kind of 1- substituted isoquinoline ketone compound and preparation method thereof | 复旦大学 | 2019-10-11 | — | — | CN | disclosed |
| CN-105101967-B | As thrombocytin 5-HT2CThe benzazepines of receptors ligand and its application | 雅培控股公司 | 2019-06-28 | — | — | CN | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190119248-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-04-25 | — | — | US | disclosed |
| US-10266532-B2 | Tricyclic modulators of TNF signaling | ABBVIE INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-3468954-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| WO-2019053634-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE GLOBAL LIMITED (BM) | 2019-03-14 | — | — | US | disclosed |
| US-20190055199-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| EP-3027608-B1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2019-02-20 | — | — | EP | disclosed |
| EP-3440069-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GlaxoSmithKline Intellectual Property (No. 2) Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10150761-B2 | Substituted pyridine-piperazinyl analogues as RSV antiviral compounds | JANSSEN SCIENCES IRELAND UC (IE) | 2018-12-11 | — | — | US | disclosed |
| CN-108884070-A | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | 葛兰素史克知识产权第二有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-20180298025-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. | 2018-10-18 | — | — | US | disclosed |
| WO-2018161022-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2018154519-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| EP-2938345-B1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING CO (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3351533-A1 | BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2018-07-25 | — | — | EP | disclosed |
| CN-108290838-A | Biaryl derivatives and drugs containing the same | 科研制药株式会社 | 2018-07-17 | — | — | CN | disclosed |
| US-20180179198-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-06-28 | — | — | US | disclosed |
| CN-105683183-B | The pyridine being substituted-piperazinyl analog as RSV antiviral compounds | 爱尔兰詹森科学公司 | 2018-06-22 | — | — | CN | disclosed |
| US-9981909-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| EP-3288939-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9856253-B2 | Tricyclic modulators of TNF signaling | ABBVIE, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017174621-A1 | PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-12 | — | — | US | disclosed |
| US-20170226395-A1 | THERMAL ENERGY STORAGE PHASE CHANGE MATERIALS COMPRISING BORONIC ACIDS AND METHODS OF MAKING AND USING THEM | ENTROPY SOLUTIONS LLC (US) | 2017-08-10 | — | — | US | disclosed |
| EP-2920189-B1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INT (DE) | 2017-08-02 | — | — | EP | disclosed |
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-23 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3140294-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2017040450-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-09 | — | — | WO | disclosed |
| EP-2668168-B1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2978757-B1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-3122721-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016168641-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304517-A1 | TRICYCLIC MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2691393-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| CN-105837560-A | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | 埃姆比特生物科学公司 | 2016-08-10 | — | — | CN | disclosed |
| US-20160168124-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | US | disclosed |
| EP-3027608-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2016-06-08 | — | — | EP | disclosed |
| CN-105601619-A | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP | 2016-05-25 | — | — | CN | disclosed |
| CN-103370298-B | method of making indeno-fused naphthol materials | TRANSITIONS OPTICAL, INC. (US) | 2016-05-25 | — | — | CN | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9309188-B2 | Method for allylating and vinylating aryl, heteroaryl, alkyl, and alkene halogenides using transition metal catalysis | Saitigo GmbH (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9308207-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9284277-B2 | Benzazepines as serotonin 5-HT2C receptor ligands and uses thereof | ABT HOLDING COMPANY (US) | 2016-03-15 | — | — | US | disclosed |
| CN-101573343-B | The pyrimidine of the 6-replacement of HIV inhibiting | JANSSEN R&D IRELAND (IE) | 2016-02-24 | — | — | CN | disclosed |
| US-20160046574-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| WO-2016025536-A1 | THERMAL ENERGY STORAGE PHASE CHANGE MATERIALS COMPRISING BORONIC ACIDS AND METHODS OF MAKING AND USING THEM | ENTROPY SOLUTIONS INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| EP-2978757-A1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2016-02-03 | — | — | EP | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| WO-2015184405-A1 | AROMATIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| CN-105101967-A | Benzazepines as serotonin 5-ht2c receptor ligands and uses thereof | ABT HOLDING CO | 2015-11-25 | — | — | CN | disclosed |
| WO-2015171757-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-2938345-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT Holding Company (US) | 2015-11-04 | — | — | EP | disclosed |
| US-9163046-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2015-10-20 | — | — | US | disclosed |
| WO-2015145371-A1 | ROR-GAMMA MODULATORS AND USES THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | disclosed |
| EP-2920189-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | Boehringer Ingelheim International GmbH (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-9102684-B2 | Indolinone analogues | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-9067934-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2015-06-04 | — | — | US | disclosed |
| WO-2015063791-A1 | NOVEL PROCESS FOR TOTAL SYNTHESIS OF VENLAFAXINE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-05-07 | — | — | WO | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-9006243-B2 | HIV inhibiting 6-substituted pyrimidines | JANSSEN R&D IRELAND (IE) | 2015-04-14 | — | — | US | disclosed |
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2015014836-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | JANSSEN R&D IRELAND (IE) | 2015-02-05 | — | — | WO | disclosed |
| US-8927711-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| EP-1671976-B1 | Process for the preparation of phosphorus-containing compounds and their intermediates | STANFORD RES INST INT (US) | 2014-12-03 | — | — | EP | disclosed |
| US-8889692-B2 | Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses | ASTRAZENECA AB (SE) | 2014-11-18 | — | — | US | disclosed |
| EP-2170848-B1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2014-10-22 | — | — | EP | disclosed |
| US-20140296229-A1 | INDOLINONE ANALOGUES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | US | disclosed |
| WO-2014154760-A1 | INDOLINONE ANALOGUES AS BRD4 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| US-8816112-B2 | Process for making novel chiral phosphorus ligands | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-08-07 | — | — | US | disclosed |
| EP-2760870-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20140194411-A1 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014100815-A2 | BENZAZEPINES AS SEROTONIN 5-HT2C RECEPTOR LIGANDS AND USES THEREOF | ABT HOLDING COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| WO-2014078491-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-22 | — | — | WO | disclosed |
| US-20140135506-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-15 | — | — | US | disclosed |
| US-8710061-B2 | Compounds for the reduction of β-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-04-29 | — | — | US | disclosed |
| US-8697673-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140045790-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2694491-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2691393-A1 | NOVEL BICYCLIC PYRIDINONES | Pfizer Inc (US) | 2014-02-05 | — | — | EP | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-8637525-B2 | Compounds for the reduction of beta-amyloid production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2014011120-A1 | ENDOPEROXIDES, SYNTHESIS AND USES THEREOF FOR THE TREATMENT OF NEOPLASTIC DISEASES SUCH AS CANCER | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-01-16 | — | — | WO | disclosed |
| EP-2401267-B1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND THEIR USE IN METHODS | AMBIT BIOSCIENCES CORP (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| EP-2668168-A1 | COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2013-12-04 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| US-8541522-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541521-B2 | Catalyst compounds and use thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2013-09-19 | — | — | US | disclosed |
| EP-1799639-B1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS SA (CH) | 2013-09-04 | — | — | EP | disclosed |
| WO-2013112878-A1 | MCL-1 MODULATING COMPOSITIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | WO | disclosed |
| US-20130184485-A1 | Method for Allylating and Vinylating Aryl, Heteroaryl, Alkyl, and Alkene Halogenides Using Transition Metal Catalysis | SALTIGO GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| EP-2611502-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2013062887-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GPR131 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-1637527-B1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-04-17 | — | — | EP | disclosed |
| CN-101006092-B | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same | PFIZER | 2013-04-17 | — | — | CN | disclosed |
| US-8420865-B2 | Phosphine compound, process for producing the same, and peroxide scavenger using the same | FUKUOKA UNIVERSITY (JP) | 2013-04-16 | — | — | US | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-8404915-B2 | 1) at least one diaryl-substituted diphosphine ligand; 2) a chromium metal precursor; and 3) optionally, one or more activators | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404627-B2 | Detergent comprising C10 to C40 hydrocarbyl substituted hydroxybenzoates for reducing asphaltene precipitation | INFINEUM INTERNATIONAL LIMITED (GB) | 2013-03-26 | — | — | US | disclosed |
| US-8399392-B2 | Method of reducing asphaltene precipitation in an engine utilizing a C22 hydrocarbyl salicylate | INFINEUM INTERNATIONAL LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20130030011-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2013-01-31 | — | — | US | disclosed |
| US-20130012523-A1 | PYRAZINONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | BROUGH STEPHEN (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8349851-B2 | JAK kinase modulating compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2534117-A2 | METHOD FOR ALLYLATING AND VINYLATING ARYL, HETEROARYL, ALKYL, AND ALKENE HALOGENIDES USING TRANSITION METAL CATALYSIS | Saltigo GmbH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316337-A1 | METHOD FOR PREPARING CHEMICAL COMPOUNDS OF INTEREST BY NUCLEOPHILIC AROMATIC SUBSTITUTION OF AROMATIC CARBOXYLIC ACID DERIVATIVES SUPPORTING AT LEAST ONE ELECTRO-ATTRACTIVE GROUP | UNIVERSITE DU MAINE (FR) | 2012-12-13 | — | — | US | disclosed |
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2012138776-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012131539-A1 | NOVEL BICYCLIC PYRIDINONES | PFIZER INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| EP-2493933-A2 | CATALYST COMPOUNDS AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20120211082-A1 | PHOTOELECTRIC CONVERSION DEVICE AND SOLAR CELL USING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012103297-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089181-A1 | O-SUBSTITUTED (2R,3R)-3-(3-HYDROXYPHENYL)-2-METHYL-4-PENTENOIC ACIDS AND A METHOD OF OBTAINING THE SAME | ZENTIVA, K.S. (CZ) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012089177-A1 | METHOD OF PRODUCING (2R,3R)-NA-DIMETHYL-3-(3-HYDROXYPHENYI)-2-METHYLPENTYLAMINE (TAPENTADOL) | ZENTIVA, K.S. (CZ) | 2012-07-05 | — | — | WO | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| EP-2463929-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL USING SAME | Mitsubishi Chemical Corporation (JP) | 2012-06-13 | — | — | EP | disclosed |
| CN-102473843-A | Photoelectric conversion element and solar cell using same | MITSUBISHI CHEM CORP | 2012-05-23 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20120115842-A1 | Substituted Oxindole Derivatives, Medicaments Containing Said Derivatives and Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120101091-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
| EP-2443092-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | Pfizer Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-8153830-B2 | Production method of asymmetric copper complex crystal | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2012030918-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053176-A1 | ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| EP-2401267-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-8030497-B2 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2011098375-A2 | METHOD FOR ALLYLATING AND VINYLATING ARYL, HETEROARYL, ALKYL, AND ALKENE HALOGENIDES USING TRANSITION METAL CATALYSIS | SALTIGO GMBH (DE) | 2011-08-18 | — | — | WO | disclosed |
| CN-101538268-B | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER | 2011-07-27 | — | — | CN | disclosed |
| WO-2011056424-A2 | CATALYST COMPOUNDS AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110098429-A1 | Catalyst Compounds and Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098427-A1 | Catalyst Compounds And Use Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2011-04-28 | — | — | US | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
| WO-2011038207-A1 | PHOSPHORUS-CONTAINING THYROID HORMONE RECEPTOR AGONISTS AND METHODS OF USE | METABASIS THERAPEUTICS, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
| US-7906648-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-1896434-B1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2011019616-A1 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-2284157-A1 | Quinolines useful in treating cardiovascular disease | Wyeth (US) | 2011-02-16 | — | — | EP | disclosed |
| US-7888381-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2011016576-A1 | ALANINE DERIVATIVES AS INHIBITORS OF APOPTOSIS PROTEINS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | WO | disclosed |
| US-20110015440-A1 | PHOSPHINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PEROXIDE SCAVENGER USING THE SAME | FUKUOKA UNIVERSITY (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| WO-2010146488-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-2264033-A1 | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS | SGX Pharmaceuticals, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100317659-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2010-12-16 | — | — | US | disclosed |
| EP-2258694-A1 | Amines as histamine-3 receptor ligands and their therapeutic applications | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20100240743-A1 | CANNABINOID RECEPTOR MODULATOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7790895-B2 | Quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-07 | — | — | US | disclosed |
| WO-2010099379-A1 | JAK KINASE MODULATING QUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| CN-101544604-B | Tricyclic compounds | SCHERING CORP | 2010-09-01 | — | — | CN | disclosed |
| US-20100210617-A1 | Aryl-Alkylamines And Heteroaryl-Alkylamines As Protein Kinase Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-08-19 | — | — | US | disclosed |
| WO-2010059393-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100113717-A1 | Process For Producing Substituted Metallocene Compounds For Olefin Polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2010-05-06 | — | — | US | disclosed |
| US-7709670-B2 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709645-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| WO-2010045013-A1 | PHENYL SUBSTITUTED THIENO [2,3-D] PYRIMIDINES AND THEIR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045009-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d] PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-22 | — | — | WO | disclosed |
| US-20100093721-A1 | PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093763-A1 | PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20100094036-A1 | PRODUCTION METHOD OF ASYMMETRIC COPPER COMPLEX CRYSTAL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2170848-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | AstraZeneca AB (SE) | 2010-04-07 | — | — | EP | disclosed |
| CN-101671594-A | Method for reducing asphaltene precipitation in an engine | INFINEUM INT LTD | 2010-03-17 | — | — | CN | disclosed |
| US-20100062957-A1 | Method of Reducing Asphaltene Precipitation in an Engine | INFINEUM INTERNATIONAL LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100062958-A1 | Detergent | INFINEUM INTERNATIONAL LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7671065-B2 | Pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-03-02 | — | — | US | disclosed |
| EP-1866322-B1 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20100041698-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2152670-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-02-17 | — | — | EP | disclosed |
| US-7662956-B2 | Tetrahydrobenzo[d]azepin-2-one derivatives and the use thereof for treating cardiovascular diseases | BAYER SHERING PHARMA AG (DE) | 2010-02-16 | — | — | US | disclosed |
| US-20100016317-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-21 | — | — | US | disclosed |
| CN-101626685-A | The glycine derivative that N-replaces: hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2010-01-13 | — | — | CN | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2134343-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090306056-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| EP-2114901-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | Tibotec Pharmaceuticals (IE) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114867-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| CN-101573343-A | HIV inhibiting 6-substituted pyrimidines | TIBOTEC PHARM LTD (IE) | 2009-11-04 | — | — | CN | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| CN-100548950-C | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-10-14 | — | — | CN | disclosed |
| US-7601839-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2106402-A1 | METHODS FOR OLIGOMERIZING OLEFINS WITH CHROMIUM PYRIDINE PHOSPHINO CATALYSTS | ExxonMobil Chemical Patents Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| WO-2009118567-A2 | PYRIMIDINES, TRIAZINES AND THEIR USE AS PHARMACEUTICAL AGENTS | THE UNIVERSITY OF NOTTINGHAM (GB) | 2009-10-01 | — | — | WO | disclosed |
| CN-101544604-A | Tricyclic compounds | SCHERING CORP (US) | 2009-09-30 | — | — | CN | disclosed |
| CN-101538268-A | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER | 2009-09-23 | — | — | CN | disclosed |
| US-7582637-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090215743-A1 | Tricyclic benzazepine derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-7579469-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-7576215-B2 | Quinolines and pharmaceutical compositions thereof | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-7566708-B2 | Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2009-07-28 | — | — | US | disclosed |
| EP-2078710-A1 | METHOD FOR PRODUCING ASYMMETRIC COPPER COMPLEX CRYSTAL | Sumitomo Chemical Company, Limited (JP) | 2009-07-15 | — | — | EP | disclosed |
| US-20090170921-A1 | Benzimidazole derivatives | NOVARTIS AG (CH) | 2009-07-02 | — | — | US | disclosed |
| CN-100503597-C | Enantioselective alkylation of tricyclic compounds | SCHERING CORP (US) | 2009-06-24 | — | — | CN | disclosed |
| US-20090143352-A1 | PYRROLO-PYRIDINE KINASE MODULATIORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7538138-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2009-05-26 | — | — | US | disclosed |
| US-7538128-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7524844-B2 | Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-04-28 | — | — | US | disclosed |
| CN-101391972-A | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2009-03-25 | — | — | CN | disclosed |
| US-7507841-B2 | Carbamoylamino-substituted 2,3-dihydro-benzofurans, indoles and benzothiophenes, e.g., (+)-N-((3R)-3-(4-isopropylphenyl)-4,6,7-trimethyl-2,3-dihydro-1-benzofuran-5-yl)-3,3-dimethylbutanamide; cerebrovascular disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090023800-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-01-22 | — | — | US | disclosed |
| US-7476752-B2 | Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters | WYETH (US) | 2009-01-13 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-20090005378-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1620102-B1 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH CORP (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-1423106-B1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | HOFFMANN LA ROCHE (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-7465815-B2 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7452880-B2 | Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1571140-B1 | C-substituted cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008132679-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008124849-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-7427679-B2 | Precursors for two-step polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7425566-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2008-09-16 | — | — | US | disclosed |
| US-7425580-B2 | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands | WYETH (US) | 2008-09-16 | — | — | US | disclosed |
| WO-2008107335-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221119-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-7417139-B2 | Method for polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-20080188633-A1 | Methods For Oligomerizing Olefins With Chromium Pyridine Phosphino Catalysts | SYMYX TECHNOLOGIES, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008089052-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008085653-A1 | METHODS FOR OLIGOMERIZING OLEFINS WITH CHROMIUM PYRIDINE PHOSPHINO CATALYSTS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008080964-A1 | HIV INHIBITING 6-SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-07-10 | — | — | WO | disclosed |
| CN-101213174-A | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-07-02 | — | — | CN | disclosed |
| EP-1781104-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-05-21 | — | — | EP | disclosed |
| EP-1919470-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| EP-1917245-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7361654-B2 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361764-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2008046083-A2 | USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-04-17 | — | — | WO | disclosed |
| EP-1904451-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2008-04-02 | — | — | EP | disclosed |
| EP-1896434-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFkB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20080058486-A1 | Phosphine Ligand-Metal Compositions, Complexes, and Catalysts For Ethylene Trimerizations | SYMYX TECHNOLOGIES INC. | 2008-03-06 | — | — | US | disclosed |
| EP-1888544-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20080021087-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-01-24 | — | — | US | disclosed |
| EP-1877378-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-01-16 | — | — | EP | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070293531-A1 | Muscarinic Acetycholine Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2007-12-20 | — | — | US | disclosed |
| EP-1866322-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | ExxonMobil Chemical Patents Inc. (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | BAYER HEALTHCARE AG (DE) | 2007-12-13 | — | — | US | disclosed |
| EP-1858853-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| US-7297692-B2 | 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2007-11-20 | — | — | US | disclosed |
| EP-1853564-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | Janssen Pharmaceutica N.V. (BE) | 2007-11-14 | — | — | EP | disclosed |
| EP-1853538-A2 | MODULATOR | UCL Biomedica plc (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20070238728-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-11 | — | — | US | disclosed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| US-20070232608-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-10-04 | — | — | US | disclosed |
| US-7273952-B2 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1831197-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831238-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | Berry & Associates , Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070203160-A1 | p38 MAP kinase inhibitors and methods for using the same | ROCHE PALO ALTO LLC | 2007-08-30 | — | — | US | disclosed |
| CN-101006092-A | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and therapeutic agents using the same | PFIZER (US) | 2007-07-25 | — | — | CN | disclosed |
| US-7238841-B2 | Polymer-supported phosphorus ligands for catalysts | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1799639-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | Glenmark Pharmaceuticals S.A. (CH) | 2007-06-27 | — | — | EP | disclosed |
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-07 | — | — | US | disclosed |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2007-05-10 | — | — | US | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781654-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1208108-B1 | POLYMERISATION PROCESS CATALYSED BY A BIDENTATE BISPHOSPHINE-GROUP VIII METAL COMPLEX | INEOS EUROPE LTD (GB) | 2007-05-09 | — | — | EP | disclosed |
| EP-1781104-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2007-05-09 | — | — | EP | disclosed |
| US-20070099990-A1 | Cannabinoid receptor modulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1776362-A1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | Virochem Pharma Inc. (CA) | 2007-04-25 | — | — | EP | disclosed |
| US-7205323-B2 | Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACEUTICALS S.A. (CH) | 2007-04-17 | — | — | US | disclosed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7193077-B2 | Exocyclic amine triaryl methyl protecting groups in two-step polynucleotide synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20070054935-A1 | Novel pyridine derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-20070054936-A1 | Novel quinoline derivatives as potassium ion channel openers | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-08 | — | — | US | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| WO-2007023105-A1 | FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007022946-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2007-03-01 | — | — | WO | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-7179926-B2 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| EP-1747192-A1 | (DIARYL-METHYL)-MALONONITRILES AND THEIR USE AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070004703-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-01-04 | — | — | US | disclosed |
| EP-1737835-A2 | DERIVATIVES OF DIHYDRONEPETALACTONE AND METHOD FOR PREPARATION | E.I.Du pont de nemours and company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006136830-A1 | ARYL-ALKYLAMINES AND HETEROARYL-ALKYLAMINES AS PROTEIN KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1720878-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006117760-A1 | ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | disclosed |
| EP-1315700-B1 | SUBSTITUTED 4-PHENYL-1-(1-PHENYL-CYCLOHEXYL)-1,2,3,6-TETRAHYDROPYRIDINE | GRUENENTHAL GMBH (DE) | 2006-11-02 | — | — | EP | disclosed |
| EP-1716118-A1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-7129240-B2 | 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2006-10-31 | — | — | US | disclosed |
| WO-2006113864-A2 | OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-10-26 | — | — | WO | disclosed |
| EP-1709006-A1 | BENZIMIDAZOLE DERIVATIVES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-7119086-B2 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| EP-1706413-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer HealthCare AG (DE) | 2006-10-04 | — | — | EP | disclosed |
| EP-1449845-B1 | Asymmetric phosphinoselenoic chloride and method for producing the same | PRESIDENT OF GIFU UNIVERSITY (JP) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006091800-A2 | NOVEL PYRIDINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091769-A1 | NOVEL QUINOLINE DERIVATIVES AS POTASSIUM ION CHANNEL OPENERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-31 | — | — | WO | disclosed |
| US-7098261-B2 | Polymer-supported phosphorus ligands for catalysis | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1692111-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | Wyeth, A Corporation of the State of Delaware (US) | 2006-08-23 | — | — | EP | disclosed |
| US-7094784-B2 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION (US) | 2006-08-22 | — | — | US | disclosed |
| WO-2006081035-A2 | FLUOROUS OLIGONUCLEOTIDE REAGENTS AND AFFINITY PURIFICATION OF OLIGONUCLEOTIDES | BERRY & ASSOCIATES, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| CN-1812790-A | 3-(1-naphthyl)-2-cyanopropanoic acid derivatives as estrogen receptor | WYETH CORP (US) | 2006-08-02 | — | — | CN | disclosed |
| EP-1368299-B1 | SUBSTITUTED C-CYCLOHEXYLMETHYLAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076632-A1 | SUBSTITUTED HETEROARYL AMIDE MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NFκB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060160968-A1 | Process for producing substituted metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006072458-A2 | SUBSTITUTED OXINDOLE DERIVATIVES, MEDICAMENTS CONTAINING SAID DERIVATIVES AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2006-07-13 | — | — | WO | disclosed |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | GLENMARK PHARMACETUCALS, S.A. | 2006-06-29 | — | — | US | disclosed |
| WO-2006067450-A2 | MODULATOR | UCL BIOMEDICA PLC (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-7067701-B2 | Preparation of phosphorus-containing compounds useful in the preparation of biphosphine ligands | SRI INTERNATIONAL (US) | 2006-06-27 | — | — | US | disclosed |
| WO-2006066109-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006065844-A2 | PROCESS FOR PRODUCING SUBSTITUTED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| EP-1671976-A1 | Process for the preparation of phosphorus-containing compounds and their intermediates | Sri International (US) | 2006-06-21 | — | — | EP | disclosed |
| US-7060836-B2 | Lactams as tachykinin antagonists | PFIZER, INC (US) | 2006-06-13 | — | — | US | disclosed |
| US-7060855-B2 | Asymmetric phosphinoselenoic chloride and method for producing the same | GIFU UNIVERSITY (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| EP-1102771-B1 | PREPARATION OF ORGANOLITHIUM AND ORGANOPHOSPHORUS DERIVATIVES | STANFORD RES INST INT (US) | 2006-05-03 | — | — | EP | disclosed |
| US-7034041-B2 | Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine | GRUENENTHAL GMBH (DE) | 2006-04-25 | — | — | US | disclosed |
| WO-2006040625-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2006-04-20 | — | — | WO | disclosed |
| CN-1250524-C | Method for preparing 2-cyanobiphenyl derivatives | HUAHAI PHARMACEUTICAL CO LTD Z (CN) | 2006-04-12 | — | — | CN | disclosed |
| CN-1759084-A | Process for preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS INC (US) | 2006-04-12 | — | — | CN | disclosed |
| EP-1453913-A4 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-7022788-B2 | Polymerization process catalyzed by a bidentate bisphosphine-group VIII metal complex | BP CHEMICALS LIMITED (GB) | 2006-04-04 | — | — | US | disclosed |
| EP-1637527-A1 | CANNABINOID RECEPTOR MODULATOR | Takeda Pharmaceutical Company Limited (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006017768-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| CN-1735599-A | 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands | BOEHRINGER INGELHEIM PHARMA (US) | 2006-02-15 | — | — | CN | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006014942-A1 | ARYLOXYALKYLAMINE NK-1/SSRI INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1620102-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20060014831-A1 | (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands | WYETH (US) | 2006-01-19 | — | — | US | disclosed |
| WO-2005123663-A1 | PROCESSES FOR THE PREPARATION OF 2-CYANO-3-NAPHTHALENE-1-YL-3-PHENYL-PROPIONIC ACID ALKYL OR BENZYL ESTERS | WYETH (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005121076-A1 | (DIARYL-METHYL)-MALONONITRILES AND THEIR USE AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277783-A1 | Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters | WYETH (US) | 2005-12-15 | — | — | US | disclosed |
| EP-1604738-A2 | Process for the preparation of coumarin | E.I. du Pont de Nemours and Company (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | ZENTARIS AG | 2005-12-01 | — | — | US | disclosed |
| US-6969730-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | WYETH (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1593430-A2 | Polymer-Supported phosphorus ligands for catalysts | E.I. DU PONT DE NEMOURS & COMPANY INCORPORATED (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593432-A2 | Polymer-supported phosphorus ligands for catalysis | E.I. du Pont de Nemours and Company (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1593431-A2 | Polymer-supported phosphorus ligands for catalysis | E. I. du Pont de Nemours and Company (US) | 2005-11-09 | — | — | EP | disclosed |
| CN-1224623-C | 1-phenylsulfonyl-1, 3-dihydro-2H-indol-2-one derivatives, their preparation and their therapeutic use | SANOFI ANWANTE (FR) | 2005-10-26 | — | — | CN | disclosed |
| EP-1583745-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050203091-A1 | Heteroaryl-fused pyrazolo derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-15 | — | — | US | disclosed |
| WO-2005085248-A1 | HETEROARYL-FUSED PYRAZOLO DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005068433-A9 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-09-15 | — | — | WO | disclosed |
| EP-1572693-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1571140-A1 | C-substituted cyclohexylmethylamine derivatives | Grünenthal GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005080390-A1 | IMIDAZOPYRIDINE DERIVATIVES AS BSR-3 ANTAGONISTS | BIOFOCUS DISCOVERY LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005077907-A1 | TETRAHYDROBENZO[D]AZEPIN-2- ONE DERIVATIVES AND THE USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| US-20050176770-A1 | Novel 1,3-dihydro-2H-indol-2-one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI-AVENTIS (FR) | 2005-08-11 | — | — | US | disclosed |
| WO-2005068433-A1 | BENZIMIDAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| WO-2005068472-A1 | TRICYCLIC BENZAZEPINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS USED FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | HUANG LIREN (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2005058834-A2 | QUINOLINES USEFUL IN TREATING CARDIOVASCULAR DISEASE | WYETH (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005054224-A2 | DERIVATIVES OF DIHYDRONEPETALACTONE AND METHOD FOR PREPARATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| US-20050131014-A1 | Quinolines useful in treating cardiovascular disease | WYETH (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
| EP-1512691-A1 | Protecting groups for two-step polynucleotide synthesis | Agilent Technologies Inc (US) | 2005-03-09 | — | — | EP | disclosed |
| US-6864277-B2 | 1,3-dihydro-2H-indol-2-one derivatives, method for preparing same and pharmaceutical compositions containing them | SANOFI-SYNTHELABO (FR) | 2005-03-08 | — | — | US | disclosed |
| US-20050049411-A1 | Exocyclic amine triaryl methyl protecting groups in two step polynucleotide synthesis | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-03 | — | — | US | disclosed |
| US-20050048601-A1 | Method for polynucleotide synthesis | REGENTS OF THE UNIVERSITY OF COLORADO, THE | 2005-03-03 | — | — | US | disclosed |
| US-20050049407-A1 | Precursors for two-step polynucleotide synthesis | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2005-03-03 | — | — | US | disclosed |
| EP-1510523-A1 | Precurors for two-step polynucleotide synthesis | Agilent Technologies Inc (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2005007656-A1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2005-01-27 | — | — | WO | disclosed |
| US-20050004164-A1 | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| EP-1493741-A2 | Benzo[b]thiophene compounds, intermediates, processes, compositions and methods | Eli Lilly & Company (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6825202-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-11-30 | — | — | US | disclosed |
| WO-2004099150-A2 | 3-(1-NAPHTHYL)-2-CYANOPROPANOIC ACID DERIVATIVES AS ESTROGEN RECEPTOR LIGANDS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040209938-A1 | Novel 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them | SANOFI (FR) | 2004-10-21 | — | — | US | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | disclosed |
| EP-0826683-B1 | Benzo[B]thiophene compounds, intermediates, processes, compositions, and methods | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| CN-1533387-A | 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use | ����ɳŵ��-����������˾ | 2004-09-29 | — | — | CN | disclosed |
| EP-1100781-B1 | HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180878-A1 | Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| CN-1528740-A | Method for preparing 2-cyanobiphenyl derivatives | 浙江华海药业股份有限公司 | 2004-09-15 | — | — | CN | disclosed |
| EP-1453913-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | Antex Pharma, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167356-A1 | Asymmetric phosphinoselenoic chloride and method for producing the same | GIFU UNIVERSITY | 2004-08-26 | — | — | US | disclosed |
| EP-1449845-A2 | Asymmetric phosphinoselenoic chloride and method for producing the same | President of Gifu University (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-20040162321-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-08-19 | — | — | US | disclosed |
| US-20040152707-A1 | High affinity ligands for nociceptin receptor ORL-1 | MERCK SHARP & DOHME CORP. | 2004-08-05 | — | — | US | disclosed |
| WO-2004063163-A1 | 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20040147785-A1 | Preparation of phosphorus-containing compounds useful in the preparation of biphosphine ligands | VAN GINKEL ROELOF (NL) | 2004-07-29 | — | — | US | disclosed |
| WO-2004058762-A1 | MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
| EP-1423393-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Zentaris GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| EP-1423106-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT 6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-6730695-B2 | TREATMENT OF HYPERTENSION, CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2004-05-04 | — | — | US | disclosed |
| US-6720442-B2 | REACTION LITHIUM PHOSPHINE COMPOUND WITH DIHALPHOSPHINE COMPOUND | SRI INTERNATIONAL | 2004-04-13 | — | — | US | disclosed |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING-PLOUGH CORPORATION | 2004-04-08 | — | — | US | disclosed |
| US-6716846-B2 | CONTROLLING PAIN IN MAMMALS | SCHERING CORPORATION | 2004-04-06 | — | — | US | disclosed |
| EP-1399412-A1 | PHOTOLABILE ESTERS AND THEIR USES | The Institute of Cancer Research (GB) | 2004-03-24 | — | — | EP | disclosed |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | WATERWORKS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2004010943-A2 | SUBSTITUTED BENZANILIDES AS MODULATORS OF THE CCR5 RECEPTOR | SMITHKLINE BEECHAM CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20030232891-A1 | Substituted C-cyclohexylmethylamine derivatives | GRUENENTHAL GMBH (DE) | 2003-12-18 | — | — | US | disclosed |
| EP-1370546-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030228629-A1 | Polymer-supported phosphorus ligands for catalysts | FAGAN PAUL J (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030225116-A1 | Substituted 4-phenyl-1-(1-phenylcyclohexyl)-1,2,3,6-tetrahydropyridine | GRUENENTAL GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-0977739-B1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6630604-B1 | Phosphine and phosphine oxide ligands are prepared using polymeric supports. These compounds can be easily cleaved from the support, and along with the corresponding supported compounds, used as ligands in the preparation of novel, | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-10-07 | — | — | US | disclosed |
| US-6624164-B2 | Solvates and/or hydrates exhibiting affinity for the arginine-vasopressin V1b receptors or for both V1b and V1a 1a receptors. | SANOFI-SYNTHELABO (FR) | 2003-09-23 | — | — | US | disclosed |
| EP-1140899-B1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORP (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030162767-A1 | With affinity for and selectivity towards the V1b receptors or both the V1b and V1a receptors of arginine-vasopressin | SANOFI-AVENTIS (FR) | 2003-08-28 | — | — | US | disclosed |
| WO-2003062443-A2 | NOVEL SUBSTITUTED ALKANE COMPOUNDS AND USES THEREOF | ANTEX PHARMA, INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| US-6599920-B2 | Antiestrogenic compound having fewer or no estrogen agonist properties on reproductive tissues | ELI LILLY AND COMPANY | 2003-07-29 | — | — | US | disclosed |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SANOFI-AVENTIS (FR) | 2003-07-24 | — | — | US | disclosed |
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | SANOFI (FR) | 2003-06-19 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
| US-20030109754-A1 | Preparation of phosphorus-containing compounds useful in the preparation of biphosphine ligands | VAN GINKEL ROELOF (NL) | 2003-06-12 | — | — | US | disclosed |
| US-20030104476-A1 | Polymer-supported phosphorus ligands for catalysis | FAGAN PAUL J (US) | 2003-06-05 | — | — | US | disclosed |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| US-20030073690-A1 | High affinity ligands for nociceptin receptor ORL-1 | MERCK SHARP & DOHME CORP. | 2003-04-17 | — | — | US | disclosed |
| US-6548708-B1 | Reacting phosphineamine, oxyphosphine or thiophosphine with organic halide; forming polymerization catalyst complexes to make carbon monoxide-A-olefin copolymers | SRI INTERNATIONAL | 2003-04-15 | — | — | US | disclosed |
| US-20030069254-A1 | New arylsulfonyl derivatives with 5-HT6 receptor affinity | SYNTEX (U.S.A.) LLC | 2003-04-10 | — | — | US | disclosed |
| WO-2003020731-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | ZENTARIS GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| EP-1131313-B1 | ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS | SCHERING CORP (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2003014097-A1 | ARYLSULFONYL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| US-20030018141-A1 | Polymerisation process catalysed by a bidentate bisphosphine-group VIII metal complex | BP CHEMICALS LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| WO-2003000644-A1 | PHOTOLABILE ESTERS AND THEIR USES | THE INSTITUTE OF CANCER RESEARCH (GB) | 2003-01-03 | — | — | WO | disclosed |
| US-20020183309-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2002-12-05 | — | — | US | disclosed |
| EP-1258244-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002074758-A2 | NOVEL AMINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6455527-B2 | ANALGESICSANALGESICS, ANXIOLYTIC AGENTS, ANTHISTAMINES, ANTIDEPRESSANTS | SCHERING CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-6448260-B2 | 3-(2-CARBOXYMETHOXY-4-METHOXYPHENYL)-1-(3,4-METHYLENEDIOXY -PHENYL)-5-(PROP-1-YLOXY)-INDANE-2-CARBOXYLIC ACID AS AN ESPECIALLY PREFERRED COMPOUND; HYPOTENSIVE AGENTS; CARDIOVASCULAR, UROGENITAL AND RESPIRATORY DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-09-10 | — | — | US | disclosed |
| US-6448265-B1 | CORTICOTROPIN RELEASING FACTOR(CRF); ANTIDEPRESSANT; (5-AMINO-1-(2,6-DICHLORO-4-TRIFLUOROMETHYLPHENYL)-3-METHYLSULFANYL-1H -PYRAZOL-4-YL)-(2,5-DIMETHYLPHENYL)METHANONE FOR EXAMPLE | PFIZER, INC. | 2002-09-10 | — | — | US | disclosed |
| US-6441018-B2 | TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES. | PFIZER INC. | 2002-08-27 | — | — | US | disclosed |
| US-6423725-B1 | ANALGESICS | PFIZER INC | 2002-07-23 | — | — | US | disclosed |
| EP-1049689-B1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1208108-A1 | POLYMERISATION PROCESS CATALYSED BY A BIDENTATE BISPHOSPHINE-GROUP VIII METAL COMPLEX | BP Chemicals Limited (GB) | 2002-05-29 | — | — | EP | disclosed |
| EP-0826670-B1 | Naphthalene compounds, intermediates, formulations, and methods | LILLY CO ELI (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1200087-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2002-05-02 | — | — | EP | disclosed |
| US-20020049227-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHAN (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
| EP-1178993-A1 | THIAZOLODERIATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Knoll GmbH (DE) | 2002-02-13 | — | — | EP | disclosed |
| US-20020016333-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONISTIC ACTIVITY | FARACI WILLIAM STEPHEN (US) | 2002-02-07 | — | — | US | disclosed |
| US-20020002177-A1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-01-03 | — | — | US | disclosed |
| CN-1326454-A | Enantioselective alkylation of tricyclic compounds | SCHERING CORP (US) | 2001-12-12 | — | — | CN | disclosed |
| EP-0826680-B1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods of preparation thereof. | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6307048-B1 | Enantioselective alkylation of tricyclic compounds | SCHERING CORPORATION | 2001-10-23 | — | — | US | disclosed |
| EP-1140899-A1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0612244-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-09-19 | — | — | EP | disclosed |
| EP-1131313-A1 | ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6288233-B1 | Enantioselective alkylation of tricyclic compounds | SCHERING CORPORATION | 2001-09-11 | — | — | US | disclosed |
| US-6274737-B1 | CARDIOVASCULAR DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-08-14 | — | — | US | disclosed |
| US-6271399-B1 | METHYL 3-(3,4-METHYLENEDIOXYPHENYL)-6-(PROP-1-YLOXY)-INDANE-2-CARBOXYLATE DERIVATIVES | SMITHKLINE BEECHAM CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6271378-B1 | Process for preparing tricyclic compounds having antihistaminic activity | SCHERING CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-20010011092-A1 | High affinity ligands for nociceptin receptor ORL-1 | MERCK SHARP & DOHME CORP. | 2001-08-02 | — | — | US | disclosed |
| US-6262066-B1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING CORPORATION | 2001-07-17 | — | — | US | disclosed |
| EP-1109786-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-27 | — | — | EP | disclosed |
| EP-1102771-A2 | PREPARATION OF ORGANOLITHIUM AND ORGANOPHOSPHORUS DERIVATIVES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2001-05-30 | — | — | EP | disclosed |
| EP-1100781-A1 | HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| CN-1288464-A | 4- (2-keto-1-benzimidazolinyl) piperidine compounds as ORL-1 receptor agonists | PFIZER PHARMA (US) | 2001-03-21 | — | — | CN | disclosed |
| WO-2001010876-A1 | POLYMERISATION PROCESS CATALYSED BY A BIDENTATE BISPHOSPHINE-GROUP VIII METAL COMPLEX | BP CHEMICALS LIMITED (GB) | 2001-02-15 | — | — | WO | disclosed |
| WO-2001007050-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| US-6177450-B1 | MIXTURE OF PERHYDROISOINDENE COMPOUND AND BENEZAMIDE COMPOUND | AVENTIS PHARMA S.A. | 2001-01-23 | — | — | US | disclosed |
| WO-2000071549-A1 | THIAZOLODERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | KNOLL GMBH (DE) | 2000-11-30 | — | — | WO | disclosed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | disclosed |
| US-6103900-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST WHICH TREAT STRESS-INDUCED DISEASES | PFIZER INC (US) | 2000-08-15 | — | — | US | disclosed |
| US-6087389-A | TREATING CARDIOVASCULAR AND RENAL DISEASES INCLUDING HYPERTENSION, ACUTE AND CHRONIC RENAL FAILURE, CYCLOSPORINE INDUCED NEPHROTOXICITY, STROKE, CEREBROVASCULAR VASOSPASM, MYOCARDIAL ISCHEMIA, ANGINA, HEART FAILURE, ATHEROSCLEROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-11 | — | — | US | disclosed |
| WO-2000037457-A1 | PROCESS FOR PREPARING TRICYCLIC COMPOUNDS HAVING ANTIHISTAMINIC ACTIVITY | SCHERING CORPORATION (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-2000031064-A1 | ENANTIOSELECTIVE ALKYLATION OF TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000014067-A1 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000008030-A2 | PREPARATION OF ORGANOLITHIUM AND ORGANOPHOSPHORUS DERIVATIVES | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000006545-A1 | HIGH AFFINITY LIGANDS FOR NOCICEPTIN RECEPTOR ORL-1 | SCHERING CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0977739-A1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 2000-02-09 | — | — | EP | disclosed |
| US-6020513-A | BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-6005109-A | CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONIST ACTIVITY; EFFECTIVE IN THE TREATMENT OF A WIDE RANGE OF DISEASES INCLUDING STRESS-RELATED ILLNESSES | PFLIZER INC. (US) | 1999-12-21 | — | — | US | disclosed |
| US-5998442-A | ANTICHOLESTEROL AGENTS | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998620-A | Synthesis of intermediates useful in preparing tricyclic compounds | SCHERING CORPORATION (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0536419-B1 | TRICYCLIC TRIAZOLE DERIVATIVES, PRODUCTION AND USE THEREOF | TORAY INDUSTRIES (JP) | 1999-10-13 | — | — | EP | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | disclosed |
| EP-0674624-B1 | PYRAZOLES HAVING CRF ANTAGONIST ACTIVITY | PFIZER (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5817693-A | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 1998-10-06 | — | — | US | disclosed |
| WO-1998042676-A1 | SYNTHESIS OF INTERMEDIATES USEFUL IN PREPARING TRICYCLIC COMPOUNDS | SCHERING CORPORATION (US) | 1998-10-01 | — | — | WO | disclosed |
| US-5789623-A | Process for the preparation of hydroxybiarylphosphines and novel compounds of this group of substances | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-08-04 | — | — | US | disclosed |
| US-5773612-A | VASOPRESSIN OR OXYTOCIN RECEPTORS | SANOFI (FR) | 1998-06-30 | — | — | US | disclosed |
| US-5739351-A | NEUROKININ A ANTAGONISTS | RHONE-POULENC RORER S.A. (FR) | 1998-04-14 | — | — | US | disclosed |
| US-5731455-A | ALKYL 2-ALKYLACYLACRYLATE CHEMICAL INTERMEDIATE; ANTICHOLESTEROL AGENTS | SHIONOGI & CO., LTD. (JP) | 1998-03-24 | — | — | US | disclosed |
| EP-0826683-A1 | Benzo[B]thiophene compounds, intermediates, processes, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826670-A1 | Naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| EP-0826680-A1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
| US-5719183-A | HYPOTENSIVE AGENTS; KIDNEY DISEASES; ANTIISCHEMIC AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5719182-A | TREATING HYPERTENSION, RENAL FAILURE, CEREBROVASCULAR DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| US-5716984-A | INDANE AND INDENE DERIVATIVES; TREATMENT OF CARDIOVASCULAR DISORDERS, KIDNEY DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-02-10 | — | — | US | disclosed |
| US-5712303-A | ANTIDEPRESSANTS | PFIZER INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5683998-A | ANTIINFLAMMATORY AGENTS, ANTIALLERGENS, ANTIPAF AGENTS | TORAY INDUSTRIES, INC. (JP) | 1997-11-04 | — | — | US | disclosed |
| US-5631279-A | ANTAGONISTS OF NEUROKININ A | RHONE-POULENC RORER, S.A. (FR) | 1997-05-20 | — | — | US | disclosed |
| US-5624950-A | USEFUL IN TREATMENT OF ANALGESIA, INFLAMMATION, ASTHMA, ALLERGIES, CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS, IMMUNE SYSTEM DISORDERS, ANTISPASMODIC AGENTS, ANTIEMETIC AGENTS | RHONE-POULENC RORER S.A. (FR) | 1997-04-29 | — | — | US | disclosed |
| CN-1034569-C | ET (ENDOTHELIN) receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1997-04-16 | — | — | CN | disclosed |
| US-5594023-A | 1,3-dihydroindol-2-one derivatives substituted in the 3-position by a nitrogen-containing group, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-01-14 | — | — | US | disclosed |
| EP-0748811-A1 | Process for the preparation of hydroxybiarylphosphanes and novel compounds from this materials group | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-18 | — | — | EP | disclosed |
| EP-0597107-B1 | LIGNAN ANALOG, PRODUCTION THEREOF, AND HYPOLIPIDEMIC DRUG | SHIONOGI & CO (JP) | 1996-07-03 | — | — | EP | disclosed |
| US-5502216-A | ANTICHOLESTEROL | SHIONOGI & CO., LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
| EP-0701991-A1 | Process for the preparation of lignin analogues and starting materials therefor | SHIONOGI & CO., LTD. (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5484804-A | Perhydroisoindole derivatives as antagonists of substance P | RHONE-POULENC RORER S.A. (FR) | 1996-01-16 | — | — | US | disclosed |
| WO-1995035295-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-12-28 | — | — | WO | disclosed |
| EP-0494419-B1 | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON SPA (IT) | 1995-12-06 | — | — | EP | disclosed |
| US-5463077-A | Exhibit substance P antagonist activity | RHONE-POULENC RORER S.A. (FR) | 1995-10-31 | — | — | US | disclosed |
| EP-0674624-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| US-5449814-A | Dehydration; Michael condensation | SHIONOGI & CO., LTD. (JP) | 1995-09-12 | — | — | US | disclosed |
| US-5420333-A | Hydroxy ketone compounds | SHIONOGI & CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0612244-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-17 | — | — | EP | disclosed |
| US-5412143-A | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.P.A. (IT) | 1995-05-02 | — | — | US | disclosed |
| EP-0612244-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-31 | — | — | EP | disclosed |
| WO-1994013643-A1 | PYRAZOLES AND PYRAZOLOPYRIMIDINES HAVING CRF ANTAGONIST ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| EP-0597107-A1 | LIGNAN ANALOG, PRODUCTION THEREOF, AND HYPOLIPIDEMIC DRUG | SHIONOGI & CO., LTD. (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-5312975-A | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.P.A. (IT) | 1994-05-17 | — | — | US | disclosed |
| CN-1073161-A | ET (ENDOTHELIN) receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1993-06-16 | — | — | CN | disclosed |
| WO-1993008799-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0536419-A1 | TRICYCLIC TRIAZOLE DERIVATIVE, PRODUCTION THEREOF, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0494419-A2 | Process for the preparation of 5-(2,4-difluorophenyl)-salicylic acid | ZAMBON GROUP S.p.A. (IT) | 1992-07-15 | — | — | EP | disclosed |
| EP-0412797-A2 | The therapeutic use of substituted benzenes, formulations thereof and novel substituted benzenes | MERCK SHARP & DOHME LTD. (GB) | 1991-02-13 | — | — | EP | disclosed |
| EP-0386940-A1 | 6-Beta-(alpha-etherified oxymino)-acyl amino penicillins | BEECHAM GROUP PLC (GB) | 1990-09-12 | — | — | EP | disclosed |
| US-4918231-A | REACTING A SILYLATED CYANOHYDRIN WITH GRIGNARD REAGENT; TREATING WITH REDUCING AGENT; HYDROLYSIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| EP-0170517-B1 | PROCESS FOR THE PRODUCTION OF 1,2-AMINO ALCOHOLS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-12-27 | — | — | EP | disclosed |
| US-4874897-A | REACTING ALKOXYPHENYL GRIGNARD WITH PHOSPHORUS TRIHALIDE, ALKALI METAL HYDRIDE, HYDROLYZING, REACTING WITH DIHALOPROPANE | SHELL OIL COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0290075-A2 | Novel diaryl phosphides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-11-09 | — | — | EP | disclosed |
| US-4710513-A | Substituted pyranone inhibitors of cholesterol synthesis | MERCK & CO., INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0221368-A2 | Substituted 1,1,2-triphenyl-1-butene | ASTA Pharma Aktiengesellschaft (DE) | 1987-05-13 | — | — | EP | disclosed |
| EP-0170517-A2 | Process for the production of 1,2-amino alcohols | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1986-02-05 | — | — | EP | disclosed |
| US-4567289-A | ANTICHOLESTEROL ANTILIPEMIC | MERCK & CO., INC. (US) | 1986-01-28 | — | — | US | disclosed |
| EP-0024348-B1 | SUBSTITUTED 6-PHENETHYL-AND PHENYLETHENYL-3,4,5,6-TETRAHYDRO-4-HYDROXYTETRAYDROPYRAN-2-ONES IN THE4-R TRANS STEREOISOMERIC FORMS AND THE CORRESPONDING DIHYDROXY ACIDS, PROCESS FOR PREPARING AND PHARMACEUTICAL COMPOSITION COMPRISING THEM | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4533668-A | N-ARALKYL AND N-ARALKENYLMORANOLINES | NIPPON SHINYAKU CO. LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4499287-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4497951-A | Ethynyl-phenylene-substituted-1,3,5-triazine derivatives and process for their production | HUGHES AIRCRAFT COMPANY (US) | 1985-02-05 | — | — | US | disclosed |
| US-4459422-A | Substituted pyranone inhibitors of cholesterol synthesis | MERCK & CO., INC. (US) | 1984-07-10 | — | — | US | disclosed |
| US-4456761-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1984-06-26 | — | — | US | disclosed |
| US-4442278-A | Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same | HUGHES AIRCRAFT COMPANY (US) | 1984-04-10 | — | — | US | disclosed |
| EP-0024943-B1 | 5,6,7-TRINOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TORAY INDUSTRIES, INC. (JP) | 1983-08-17 | — | — | EP | disclosed |
| US-4375475-A | ANTICHOLESTEROL AGENTS | MERCK & CO., INC. (US) | 1983-03-01 | — | — | US | disclosed |
| US-4356182-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-10-26 | — | — | US | disclosed |
| US-4316905-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
| US-4301164-A | FOR USE AS ANTIULCER AGENTS, HYPOTENSIVE AGENTS, ANTITHROMBOSIC AGENTS | TORAY INDUSTRIES, INC. (JP) | 1981-11-17 | — | — | US | disclosed |
| US-4291040-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-09-22 | — | — | US | disclosed |
| US-4272530-A | ESTROGENIC ACTIVITY | ROUSSEL UCLAF (FR) | 1981-06-09 | — | — | US | disclosed |
| EP-0024943-A1 | 5,6,7-Trinor-4,8-inter-m-phenylene PGI2 derivatives and pharmaceutical compositions containing them | TORAY INDUSTRIES, INC. (JP) | 1981-03-11 | — | — | EP | disclosed |
| EP-0024348-A1 | Substituted 6-Phenethyl-and phenylethenyl-3,4,5,6-tetrahydro-4-hydroxytetraydropyran-2-ones in the4-R trans stereoisomeric forms and the corresponding dihydroxy acids, process for preparing and pharmaceutical composition comprising them | MERCK & CO. INC. (US) | 1981-03-04 | — | — | EP | disclosed |
| US-4233296-A | STEROIDS HAVING PROGESTOMIMETIC PROPERTIES | ROUSSEL UCLAF (FR) | 1980-11-11 | — | — | US | disclosed |
| US-4147695-A | 11β-Substituted-Δ9 -steroids | ROUSSEL UCLAF (FR) | 1979-04-03 | — | — | US | disclosed |
| US-4147695-A | 11β-Substituted-Δ9 -steroids | ROUSSEL UCLAF (FR) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015440-A1 | PHOSPHINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PEROXIDE SCAVENGER USING THE SAME | FECH, PRDX5, MTCH2 | CA1 1141/4885CA2 452/4885CA7 1485/4885 |
| US-20100062958-A1 | Detergent | HDHD5, DSG1, HSD17B10 | CA1 319/4885CA2 86/4885CA7 88/4885 |
| US-20150150874-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | CA1 4854/4885CA2 4340/4885CA7 4647/4885 |
| US-20030139413-A1 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | AVPR2, AVPR1B, AVPR1A | CA1 1186/4885CA2 547/4885CA7 2613/4885 |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | CA1 2664/4885CA2 4410/4885CA7 4703/4885 |
| US-20140221371-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, HTR1A, HTR2C | CA1 4580/4885CA2 4833/4885CA7 4882/4885 |
| US-20040167356-A1 | Asymmetric phosphinoselenoic chloride and method for producing the same | PHOSPHO1, AGPAT5, PLCB1 | CA1 2133/4885CA2 741/4885CA7 1010/4885 |
| US-20210238159-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | RNASE1, GTF3C4, POLRMT | CA1 4169/4885CA2 3940/4885CA7 3057/4885 |
| US-20050277783-A1 | Processes for the preparation of 2-cyano-3-naphthalene-1-yl-3-phenyl-propionic acid alkyl or benzyl esters | PCCA, PAH, CYP7A1 | CA1 2022/4885CA2 781/4885CA7 298/4885 |
| US-20070105820-A1 | Oxindole compounds and their uses as therapeutic agents | OPRL1, OPRK1, TRPV1 | CA1 1475/4885CA2 316/4885CA7 2323/4885 |
| US-20090170921-A1 | Benzimidazole derivatives | CYP3A7, UGT2B7, CYP2B6 | CA1 3733/4885CA2 2120/4885CA7 274/4885 |
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | CA1 4603/4885CA2 2113/4885CA7 4311/4885 |
| US-20030114683-A1 | Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors | AVPR1B, AVPR1A, AVPR2 | CA1 384/4885CA2 229/4885CA7 1741/4885 |
| US-20230115176-A1 | Complement Modulators and Related Methods | C5, C9, C1QBP | CA1 4675/4885CA2 4556/4885CA7 4181/4885 |
| US-20060142585-A1 | Novel dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation | DPP4, DPP3, DPP7 | CA1 3460/4885CA2 1778/4885CA7 1888/4885 |
| US-20050256132-A1 | Use of ER selective NF-kB inhibitors for the treatment of sepsis | NFKBIA, IKBKB, NFKB2 | CA1 4729/4885CA2 3776/4885CA7 4529/4885 |
| US-20140296229-A1 | INDOLINONE ANALOGUES | CCNT1, CCNA1, MKI67 | CA1 3817/4885CA2 1750/4885CA7 2843/4885 |
| US-20140135506-A1 | PROCESS FOR MAKING NOVEL CHIRAL PHOSPHORUS LIGANDS | PHOSPHO1, INPP5B, PLCG2 | CA1 973/4885CA2 553/4885CA7 935/4885 |
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | CA1 3697/4885CA2 2725/4885CA7 1220/4885 |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP1A2, CYP3A43, CYP4A22 | CA1 2665/4885CA2 1243/4885CA7 275/4885 |
| US-20200277275-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | CA1 2133/4885CA2 1240/4885CA7 2681/4885 |
| US-20070129400-A1 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and use thereof | NR0B1, NR3C1, NFKB2 | CA1 3726/4885CA2 2871/4885CA7 3988/4885 |
| US-20170291891-A1 | SUBSTITUTED PYRIDINE-PIPERAZINYL ANALOGUES AS RSV ANTIVIRAL COMPOUNDS | MAVS, ZC3HAV1, PIR | CA1 4883/4885CA2 4424/4885CA7 4350/4885 |
| US-10829473-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-20070299105-A1 | 2-Cyanopropanoic Acid Amide and Ester Derivatives and Methods of Their Use | HCAR2, PCCA, MCCC2 | CA1 195/4885CA2 61/4885CA7 159/4885 |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CA1 2408/4885CA2 1756/4885CA7 2528/4885 |
| US-12404448-B2 | Dihydroquinoline photochromic compounds | CBR3, CBR1, RECQL | CA1 3847/4885CA2 1771/4885CA7 1444/4885 |
| US-20200277276-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-20060020019-A1 | Aryloxyalkylamine NK-1/SSRI inhibitors | TPH1, SLC6A4, HTR1A | CA1 2186/4885CA2 2218/4885CA7 2914/4885 |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | CA1 4470/4885CA2 3364/4885CA7 4438/4885 |
| US-20060154973-A1 | Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKB2, NFKB1 | CA1 3724/4885CA2 2871/4885CA7 2781/4885 |
| US-20110098427-A1 | Catalyst Compounds And Use Thereof | THEM6, OPRM1, NOTUM | CA1 3486/4885CA2 3371/4885CA7 2982/4885 |
| US-20130245014-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK3, JAK1 | CA1 4854/4885CA2 4340/4885CA7 4647/4885 |
| US-20200277274-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | CA1 4767/4885CA2 4148/4885CA7 4743/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | CA1 2133/4885CA2 1240/4885CA7 2681/4885 |
| US-20050148570-A1 | Novel substituted alkane compounds and uses thereof | ALK, CYP11B2, ALKBH2 | CA1 2184/4885CA2 2113/4885CA7 399/4885 |
| US-10934272-B2 | Pyridyl derivatives as bromodomain inhibitors | BRD4, BRD3, BRDT | CA1 3893/4885CA2 3272/4885CA7 4456/4885 |
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | SLC26A3, PRDX4, PRDX2 | CA1 22/4885CA2 12/4885CA7 146/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | CA1 4603/4885CA2 2113/4885CA7 4311/4885 |
| US-20190077784-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, SLC47A1, SCNN1A | CA1 4846/4885CA2 1799/4885CA7 4290/4885 |
| US-20210024537-A1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | ACACA, ACACB, ACAT2 | CA1 1233/4885CA2 1306/4885CA7 1255/4885 |
| US-20030228629-A1 | Polymer-supported phosphorus ligands for catalysts | PHOSPHO1, PSPH, PNKP | CA1 1416/4885CA2 1481/4885CA7 1276/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | CA1 4169/4885CA2 3940/4885CA7 3057/4885 |
| US-20070287698-A1 | Tetrahydrobenzo(D)Azepin-2-One Derivatives and the Use Thereof for Treating Cardiovascular Diseases | APOB, PCSK9, BDKRB1 | CA1 4883/4885CA2 4863/4885CA7 4865/4885 |
| US-10647675-B2 | Biaryl derivative and medicine containing same | MAN2B1, CBR3, MANBA | CA1 2862/4885CA2 592/4885CA7 812/4885 |
| US-20040152707-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OGFRL1, OPRD1 | CA1 1612/4885CA2 1352/4885CA7 4007/4885 |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PROKR1, TACR2, TACR1 | CA1 1502/4885CA2 1227/4885CA7 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.